#IMS25 In my mind, this will be the slayer of ASCT more than any other #MMsm regimen... Excellent Tec-DVR & Tec-DR data [1x weekly Velcade & lots of IVIG 👏] in NDMM from MajesTEC-5 Marc S. Raab 100% ORR, 100% MRD neg across the board. This is what we hope for with induction!

And #IMS25 Marc S. Raab adding that they even switched from NGF to NGS at 10^-6 to be sure... still 100% MRD neg across the board. Truly remains the best induction data in #MMsm the world has ever seen... and my guess is that IVIG is helping to lower AE profile substantially!

The only time where you will hear me advocating for more dex… * * but we of course need prospective research to see whether dex 10 BID can do the trick to restrain ALC and prevent MNTs after CAR-T… more to come! #IMS25 #MMsm

Great interest in the #Nursing & #AlliedHealth posters today 📈 Browse the abstracts on the #IMS25 app if you missed the session 👀 #myeloma Myeloma Society

#OnlineFirst The Two Sides of Bispecific Antibodies in Multiple Myeloma: Where Trial Promise Meets Real-World Practice by #IMS25 presenter Sonja Zweegman and colleagues doi.org/10.1158/2643-3…

One slide summarized it all! By ⁦Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰⁩ at #IMS2025 #IMS25

Annual meeting of ⁦Myeloma Society⁩ Penultimate day in Toronto. #IMS25

High risk genomic validation in a large cohort of NDMM using NGS! #IMS2025

Belantamab Mafodotin Triplet Yields Responses With Low Ocular Toxicity in Intermediate-Fit or Frail Newly Diagnosed Myeloma University of Athens Myeloma Society #IMS25 #mmsm #hematology onclive.com/view/belantama…

It’s the final day of #IMS25! Check the program for today’s highlights and don’t miss the Debate on ADCs, Bispecifics or CART later today! bit.ly/3K8T4QU

Its a wrap…..see you in 🏴󠁧󠁢󠁳󠁣󠁴󠁿🐮Monica Morris Beth Faiman PhD Tina Crosbie Rahul Banerjee, MD, FACP Georgia McCaughan Mary Steinbach

Thanks Noopur Raje for mentorship, Meera Mohan Kai Rejeski et al for excellent insights! Trials of IgG replacement with bsAbs in #MMsm should be done: IVIG vs SCIG, flat-dose vs wt-based, when to stop. But for Cycle 1 - this is like acyclovir in terms of simple safety step!

Findings from the phase 2 ISASOCUT study support the use of subcutaneous isatuximab plus VRd as a new standard of care in newly diagnosed MM, said Arthur Bobin of CHU de Poitiers, who presented these results at #IMS25. #IMS2025 #mmsm shorturl.at/iSblj

#BOPA2025 5km 🏃🏃‍♀️ in Belfast this morning! Well done team. Great way to start the conference weekend 🤩

Day 1 about to start! Looking forward to learning lots from BOPA Committee at #BOPA2025

Biggest & best #downwithdex study yet - IFM 2017-03 by Manier et al in The Lancet Oncology 👏 Dara-R (dex 20mg weekly for 2 cycles, then stop, not needed as pre-med) drastically outperformed Rd. Stopping dex after 2 cycles: better tolerability & better efficacy. This is the way!

#BOPA2025 Great to see dual hats of ISOPP at BOPA Committee

Thoughts from Day 1 #BOPA2025 - Good news for Day 2️⃣ we have ⛅️ and blue sky!

Last session of the day! BOPA Committee #BOPA2025

Starting Day 3 of #BOPA2025 with a behind the scene look at cancer therapy 🎯 with Dr Elaine Vickers BOPA Committee